Imcarbofos is diphosphoricthioamide derivative patented by American Cyanamid Co as anthelmintics agent.

Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.

Ilepcimide, a piperine derivative, was studied in China as an anticonvulsant agent for the treatment of seizures in epilepsy children patients. However, this study was discontinued.

Idramantone (Kemantane) is a biologically active compound first synthesized and pharmacologically studied at the V. V. Zakusov Science Research Institute of Pharmacology, Russian Academy of Medical Sciences. Idramantone has immunostimulatory properties, which are particularly effective in the treatment of autoimmune diseases of the vascular system of the limbs, chronic bronchitis, bronchial asthma, aphthous stomatitis, herpes, and others. Idramantone also has an antiparkinsonism action. The compound has antiamnestic properties, which experimental data indicate are comparable in strength to those of memantine. Idramantone has cerebrovascular properties, increasing the blood supply in the ischemic brain. In addition, Idramantone and its derivatives are used in the electronics industry.

Ciclactate is cyclohexanol derivative patented by N. V. Koninklijke Pharmaceutische Fabrieken Voorheen Brocades-Stheeman & Pharmacia as spasmolytics and blood vessel dilator. Ciclactate has never been marketed in the US and EU.

ilofungin is a narrow spectrum antimycotic patented by a pharmaceutical company Eli Lilly and Co in 1981. Cilofungin is particularly active against the opportunistic fungal pathogen Candida albicans. Cilofungin action is exerted through inhibition of the synthesis of (1,3)-beta-glucan, an essential cell wall component, it invades a fungus' ability to synthesize cell walls.

Metacetamol (3-hydroxyacetanilide) is a structural isomer of the widely used drug paracetamol and is being considered as a promising alternative to the latter because of its lower toxicity. 3-hydroxyacetanilide, the positional isomer of paracetamol, does not cause depletion of GSH in vivo or hepatotoxicity even though the extent of covalent binding of the reactive metabolite (in vivo or in vitro) is comparable to that for an equimolar dose of paracetamol. Metacetamol should prove to be a useful tool to aid in the discrimination of hepatic acetaminophen protein adducts that may be critical or noncritical to survival of hepatocytes

ISOPREDNIDENE is a synthetic glucocorticoid. It suppresses both the release and the synthesis of adrenocorticotropin by the pituitary gland.

(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)-3-PPP, also known as preclamol) has a dual action towards to dopamine D2 autoreceptor: it activates it and also acts concomitantly as an antagonist at postsynaptic DA receptors. It was shown, that (-)-3PPP/preclamol was a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy. Besides, the motor effects of the drug were evaluated in nine patients with Parkinson's disease using a double-blind, placebo-controlled design. However, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.

Droxinavir is hydroxyethylurea human immunodeficiency virus type 1 (HIV-1) protease inhibitor. Position 88 of HIV-1 protease gene plays a key role in the interaction between droxinavir and the protease molecule. A mutation in this position, located outside the active site, confers resistance to the hydroxyethylurea inhibitor droxinavir. The V82A and N88S substitutions conferred droxinavir resistance on HIV-1 recombinant variants. Positions 82 and 88 are reported to be variable in natural populations isolated from patients who have not been treated with protease inhibitors. Droxinavir had been in preclinical phase for the treatment of HIV-1 infection. However, this study was discontinued.